Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
about
RNA-binding protein nucleolin in diseaseRoles of nucleolin. Focus on cancer and anti-cancer therapyDNA-fragments are transcytosed across CaCo-2 cells by adsorptive endocytosis and vesicular mediated transport.Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cellsNucleolin down-regulation is involved in ADP-induced cell cycle arrest in S phase and cell apoptosis in vascular endothelial cells.Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cellsAS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands.Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.A comparative study of glycoproteomes in androgen-sensitive and -independent prostate cancer cell lines.Cell-surface nucleolin is sequestered into EPEC microcolonies and may play a role during infection.Nuclear Protein C23 on the Cell Surface Plays an Important Role in Activation of CXCR4 Signaling in Glioblastoma.Cell surface protein C23 affects EGF-EGFR induced activation of ERK and PI3K-AKT pathways.Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-α-inducing protein of Helicobacter pylori.Study of the selective uptake progress of aptamer-modified PLGA particles by liver cells.Synthesis and evaluation of an (18) F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cells.Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer.Smart bomb AS1411 aptamer-functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer.Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.
P2860
Q28390879-A5B036D2-B706-4CA0-A219-7026D94E21A3Q34047719-1788D2BE-CF22-441A-902C-ECBB7AB66E84Q34587014-87E15628-195F-445B-9F1F-D5D59BA2FE86Q35142045-F97F7283-FF5A-437B-80B5-2BB2DF321E7EQ35308865-CF31380C-02B4-4D1B-8CFA-3EB250661CF0Q36117908-0C4CAE20-D00A-4213-B1CD-F419D23285D5Q36210284-F76B6C89-08BB-43E4-BFBC-CE97F44E040BQ36370196-3F160979-752A-402D-ACD3-F4AB5C1C07BCQ37698301-712CA312-A8CF-49CD-B337-9A4484774739Q38311680-E332A29D-69D4-47D3-A581-5A4448661945Q38312065-508FB8DA-119D-41B7-83C8-B16231F8A5D7Q38325835-E268CE97-CE27-49EA-95B7-E741BF9E56EDQ38943023-30977DD3-15DE-439D-80FC-5A119F9003A5Q38976208-13C3C75C-6C41-4F82-84BB-5AEA3F7A8E71Q39061507-136F2D1A-7B69-4FE9-B6DE-B5B2278EF795Q39123634-79630A54-233C-4B5B-85B0-BFC8D86EB12EQ41593876-2AC62F5F-AD78-4600-A4EB-11EC1D48C9ADQ44428129-8BB09BB3-B9DE-49E8-BEAF-14F343BDC690Q49047930-D7EFF1B3-416E-4855-B976-71EFEFF43AA2Q49909762-33776B4C-DB29-4D40-B464-6249250A4694
P2860
Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
@en
type
label
Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
@en
prefLabel
Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
@en
P2093
P356
P1476
Nucleolin on the cell surface as a new molecular target for gastric cancer treatment.
@en
P2093
Atsushi Takahashi
Hirota Fujiki
Kazuya Hirano
Kensei Yamaguchi
Masami Suganuma
Masatoshi Beppu
Tatsuro Watanabe
P304
P356
10.1248/BPB.33.796
P577
2010-01-01T00:00:00Z